Follicular thyroid carcinoma (FTC) is responsible for approximately 10% of thyroid malignancies. Since this type of malignancy indicates no capsular and vascular invasions, adenoma and follicular carcinoma of thyroid are not distinguishable. It has been proved that microRNAs, which regulate approximately 30% of coding proteins, have an association with follicular thyroid adenoma (FTA) and carcinoma of the thyroid. Therefore, the aim of this study was to assess the expression of some miRNAs for detecting the most appropriate miRNA as potential biomarker in the diagnosis of FTA and FTC patients. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) was applied to determine the expression levels of miR-129-1, miR-146b,-183 and miR-197 in 48 cases (16 FTC, 16 FTA and 16 hyperplasia/multinodular goiter (MNG) cases). The significance of miRNA differential expression levels among groups were assessed using Multivariate test by Statistical Package for Science Software (SPSS v.20) and Graph Pad Prism v.8. Results indicated that all of the miRNAs had significant overexpression in FTC and FTA versus MNG cases, and also increased expression level in FTC in comparison with FTA, however it was not significant. The results of ROC curve analysis determined the significant overexpression and prognostic value of miR-129-1 in FTA cases and miR-146b in both FTA and FTC cases compared to MNG group. Although all of the earlier mentioned microRNAs were overexpressed in FTC and FTA cases, the ROC curve results demonstrated that miR-129-1 had agreeable AUC for FTA cases. Therefore, it seems that it's cut-off point could be helpful in distinguishing between FTA and multinodular goiter cases. On the other hand, although miR-146b has excellent diagnostic value in both FTA and FTC groups, it seems that this microRNA is unable to act as a specific biomarker to discriminate between FTA and FTC cases. This data need to be confirmed in a large cohort study and other biological samples such as plasma.

中文翻译：

---

mir-129-1，miR-146b，mir-183和mir-197在滤泡性甲状腺癌和腺瘤组织中的过表达。

甲状腺滤泡性癌（FTC）约占甲状腺恶性肿瘤的10％。由于这种类型的恶性肿瘤表明没有囊膜和血管浸润，因此甲状腺的腺瘤和滤泡癌无法区分。业已证明，调节约30％编码蛋白的microRNA与滤泡性甲状腺腺瘤（FTA）和甲状腺癌有关。因此，本研究的目的是评估一些miRNA的表达，以检测最合适的miRNA作为诊断FTA和FTC患者的潜在生物标记。应用逆转录定量聚合酶链反应（RT-qPCR）测定48例（16 FTC，16 FTA和16增生/多结节性甲状腺肿）miR-129-1，miR-146b，-183和miR-197的表达水平（MNG）案例）。使用科学软件统计软件包（SPSS v.20）和Graph Pad Prism v.8的多变量测试评估组之间miRNA差异表达水平的重要性。结果表明，与MNG病例相比，所有miRNA在FTC和FTA中均具有明显的过表达，并且与FTA相比，在FTC中的表达水平也增加，但并不显着。与MNG组相比，ROC曲线分析的结果确定了FTA病例中miR-129-1和FTA和FTC病例中miR-146b的显着过表达和预后价值。尽管前面提到的所有microRNA在FTC和FTA病例中均过表达，但ROC曲线结果表明miR-129-1在FTA病例中具有令人满意的AUC。因此，似乎 临界点可能有助于区分FTA和多结节性甲状腺肿病例。另一方面，尽管miR-146b在FTA和FTC组中均具有出色的诊断价值，但似乎该microRNA不能作为区分FTA和FTC病例的特定生物标记。需要在大型队列研究和其他生物样品（例如血浆）中确认此数据。